Sequenom Welcomes Suber Huang, M.D., to Ophthalmology Advisory Board

SAN DIEGO, Oct. 20, 2011 /PRNewswire/ -- Sequenom, Inc. (Nasdaq: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the appointment of Suber Huang, M.D., to its ophthalmology clinical advisory board.

"As a firm supporter of the use of advanced genetic testing services, I look forward to advising Sequenom in delivering solutions that will help physicians advance patient care," said Dr. Huang. "We continue to witness promising advances using next-generation technologies, and as such, my goal in this new role is to assist Sequenom management in aligning their expertise with the needs of the ophthalmology community."

Dr. Huang is President of the American Society of Retina Specialists and has served on the Steering Committee for the National Eye Health Education Program, an advisory board to the National Eye Institute/National Institutes of Health, since 2003. He is also Vice-chair and Philip F. and Elizabeth G. Searle Professor of the Department of Ophthalmology and Visual Sciences at the Case Western Reserve University and Director, Center for Retina and Macular Disease and the Retinal Diseases Image Analysis Reading Center at University Hospitals Case Medical Center. He is certified by the American Board of Ophthalmology, and serves on the Board of Directors for the Northeast Ohio Juvenile Diabetes Research Foundation and the University School. He is also Chair, Diabetic Eye Disease program at NEHEP/NEI/NIH and chair, Research, Regulatory, and Federal Affairs committee for the American Academy of Ophthalmology.

Dr. Huang received his undergraduate degree from the Johns Hopkins University, his medical degree in 1990 from the Albert Einstein College of Medicine, and his MBA in 2004 from the Weatherhead School of Management, Case Western Reserve University. He completed his ophthalmology residency training at the Wilmer Ophthalmological Institute at Johns Hopkins University and a fellowship in vitreoretinal diseases and surgery from the Bascom Palmer Eye Institute at the University of Miami.

"We welcome Dr. Huang to our advisory board as we continue to advance genetic technologies in the retinal specialty," said Ronald M. Lindsay, Ph.D., Executive Vice President, Research and Development at Sequenom. "His renowned expertise in this specialty and appreciation for the advancement of novel technologies that can help improve patient care will contribute significantly to our advisory team."

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding delivering solutions that will help physicians advance patient care, goals, advancing genetic technologies in the retinal specialty, the anticipated contribution of Dr. Huang to the Company's advisory team, and the Company's commitment to improving healthcare through revolutionary genetic analysis solutions,  are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use by customers of the Company's products and services including its ophthalmology related products, ongoing litigation involving the Company, the Company's financial position, its ability to position itself for product launches and growth and develop and commercialize new technologies and products, particularly new technologies such as diagnostics, laboratory developed tests, and genetic analysis platforms, reliance upon the collaborative efforts of other parties, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, and other risks detailed from time to time in the Company's Annual Report on Form 10-K for the year ended December 31, 2010 and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

(Logo:  http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

SOURCE Sequenom, Inc.